Shopping Cart 0
Cart Subtotal
USD 0

Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, infectious disease, and others. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs, among others. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Adimab Raises USD 13.8 Million In Series F Financing 12

Partnerships 14

Adimab Enters into Agreement with Boehringer Ingelheim 14

Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16

iTeos Therapeutics Enters into Agreement with Adimab 17

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18

Adimab Enters into Research Agreement with Kite Pharma 19

Adimab Enters into Discovery Agreement with Celgene 20

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21

Adimab Enters into Agreement with Acceleron Pharma 22

Adimab Enters into Agreement with Oncothyreon 23

Adimab Enters into Agreement with Surface Oncology 24

Adimab Enters into Agreement with Potenza Therapeutics 25

Five Prime Therapeutics Enters Into Research Agreement With Adimab 26

Jounce Therapeutics Enters Into Research Agreement With Adimab 27

Alector Enters Into Research Agreement With Adimab 28

Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29

Adimab Expands Agreement with Innovent Biologics 30

GlaxoSmithKline Expands its Partnership with Adimab 31

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32

Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33

Adimab Enters Into Co-Development Agreement With Gilead Sciences 34

Licensing Agreements 35

Eli Lilly Enters into Licensing Agreement with Adimab 35

Arsanis Enters into Licensing Agreement with Adimab 36

Kite Pharma Exercises Option for Licensing Agreement with Adimab 37

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38

Adimab Enters into Licensing Agreement with Merck 39

Adimab Enters Into Licensing Agreement With Novo Nordisk 40

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41

Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42

Mersana Therapeutics Amends its Licensing Agreement with Adimab 43

Adimab LLC-Key Competitors 44

Adimab LLC-Key Employees 45

Adimab LLC-Locations And Subsidiaries 46

Head Office 46

Recent Developments 47

Other Significant Developments 47

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 47

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 49

Jan 08, 2018: Adimab Provides Year-End Update on 2017 Partnership Activities 50

Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Deals By Therapy Area, 2012 to YTD 2018 9

Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adimab Raises USD 13.8 Million In Series F Financing 12

Adimab Enters into Agreement with Boehringer Ingelheim 14

Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16

iTeos Therapeutics Enters into Agreement with Adimab 17

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18

Adimab Enters into Research Agreement with Kite Pharma 19

Adimab Enters into Discovery Agreement with Celgene 20

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21

Adimab Enters into Agreement with Acceleron Pharma 22

Adimab Enters into Agreement with Oncothyreon 23

Adimab Enters into Agreement with Surface Oncology 24

Adimab Enters into Agreement with Potenza Therapeutics 25

Five Prime Therapeutics Enters Into Research Agreement With Adimab 26

Jounce Therapeutics Enters Into Research Agreement With Adimab 27

Alector Enters Into Research Agreement With Adimab 28

Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29

Adimab Expands Agreement with Innovent Biologics 30

GlaxoSmithKline Expands its Partnership with Adimab 31

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32

Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33

Adimab Enters Into Co-Development Agreement With Gilead Sciences 34

Eli Lilly Enters into Licensing Agreement with Adimab 35

Arsanis Enters into Licensing Agreement with Adimab 36

Kite Pharma Exercises Option for Licensing Agreement with Adimab 37

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38

Adimab Enters into Licensing Agreement with Merck 39

Adimab Enters Into Licensing Agreement With Novo Nordisk 40

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41

Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42

Mersana Therapeutics Amends its Licensing Agreement with Adimab 43

Adimab LLC, Key Competitors 44

Adimab LLC, Key Employees 45

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, infectious disease, and others. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs, among others. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Adimab Raises USD 13.8 Million In Series F Financing 12

Partnerships 14

Adimab Enters into Agreement with Boehringer Ingelheim 14

Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16

iTeos Therapeutics Enters into Agreement with Adimab 17

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18

Adimab Enters into Research Agreement with Kite Pharma 19

Adimab Enters into Discovery Agreement with Celgene 20

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21

Adimab Enters into Agreement with Acceleron Pharma 22

Adimab Enters into Agreement with Oncothyreon 23

Adimab Enters into Agreement with Surface Oncology 24

Adimab Enters into Agreement with Potenza Therapeutics 25

Five Prime Therapeutics Enters Into Research Agreement With Adimab 26

Jounce Therapeutics Enters Into Research Agreement With Adimab 27

Alector Enters Into Research Agreement With Adimab 28

Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29

Adimab Expands Agreement with Innovent Biologics 30

GlaxoSmithKline Expands its Partnership with Adimab 31

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32

Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33

Adimab Enters Into Co-Development Agreement With Gilead Sciences 34

Licensing Agreements 35

Eli Lilly Enters into Licensing Agreement with Adimab 35

Arsanis Enters into Licensing Agreement with Adimab 36

Kite Pharma Exercises Option for Licensing Agreement with Adimab 37

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38

Adimab Enters into Licensing Agreement with Merck 39

Adimab Enters Into Licensing Agreement With Novo Nordisk 40

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41

Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42

Mersana Therapeutics Amends its Licensing Agreement with Adimab 43

Adimab LLC-Key Competitors 44

Adimab LLC-Key Employees 45

Adimab LLC-Locations And Subsidiaries 46

Head Office 46

Recent Developments 47

Other Significant Developments 47

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 47

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 49

Jan 08, 2018: Adimab Provides Year-End Update on 2017 Partnership Activities 50

Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adimab LLC, Deals By Therapy Area, 2012 to YTD 2018 9

Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adimab Raises USD 13.8 Million In Series F Financing 12

Adimab Enters into Agreement with Boehringer Ingelheim 14

Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16

iTeos Therapeutics Enters into Agreement with Adimab 17

Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18

Adimab Enters into Research Agreement with Kite Pharma 19

Adimab Enters into Discovery Agreement with Celgene 20

Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21

Adimab Enters into Agreement with Acceleron Pharma 22

Adimab Enters into Agreement with Oncothyreon 23

Adimab Enters into Agreement with Surface Oncology 24

Adimab Enters into Agreement with Potenza Therapeutics 25

Five Prime Therapeutics Enters Into Research Agreement With Adimab 26

Jounce Therapeutics Enters Into Research Agreement With Adimab 27

Alector Enters Into Research Agreement With Adimab 28

Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29

Adimab Expands Agreement with Innovent Biologics 30

GlaxoSmithKline Expands its Partnership with Adimab 31

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32

Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33

Adimab Enters Into Co-Development Agreement With Gilead Sciences 34

Eli Lilly Enters into Licensing Agreement with Adimab 35

Arsanis Enters into Licensing Agreement with Adimab 36

Kite Pharma Exercises Option for Licensing Agreement with Adimab 37

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38

Adimab Enters into Licensing Agreement with Merck 39

Adimab Enters Into Licensing Agreement With Novo Nordisk 40

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41

Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42

Mersana Therapeutics Amends its Licensing Agreement with Adimab 43

Adimab LLC, Key Competitors 44

Adimab LLC, Key Employees 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS